Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly EBT of -$91.0 million for Q1 2026, down 153.29% year-over-year from $170.7 million in Q1 2025, and down 176.0% quarter-over-quarter from -$33.0 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) EBT (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' EBT history runs 6 years deep, the most recent figure standing at -$91.0 million for Q1 2026.
- In Q1 2026, EBT fell 153.29% year-over-year to -$91.0 million; the TTM figure through Mar 2026 stood at -$199.7 million (up 9.0% YoY), while the FY2025 annual figure was -$144.7 million, up 52.11% from the prior year.
- EBT for Q1 2026 stood at -$91.0 million, down from -$33.0 million in the prior quarter.
- The five-year high for EBT was $24.0 million in Q2 2023, with the low at -$118.6 million in Q1 2024.
- The 5-year median for EBT is -$41.4 million (2025), against an average of -$40.2 million.
- The sharpest annual moves came in 2023 and 2024: EBT soared 144.55% in 2023, then sank 8549.82% in 2024.
- Amylyx Pharmaceuticals' EBT stood at -$43.2 million in 2022, then jumped by 110.28% to $4.4 million in 2023, then tumbled by 959.55% to -$38.2 million in 2024, then gained by 13.69% to -$33.0 million in 2025, then sank by 176.0% to -$91.0 million in 2026.
- Business Quant data shows AMLX's EBT at -$91.0 million in Q1 2026, -$33.0 million in Q4 2025, and -$34.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 86.50 Bn | 85.53 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.71 Bn | 39.05 Bn | 2.15 Bn | -455.00 Mn |
| 3 | Zoetis | 30.86 Bn | 29.18 Bn | 1.80 Bn | 866.00 Mn |
| 4 | Takeda Pharmaceutical | 28.50 Bn | 22.70 Bn | 5.10 Bn | 1.02 Bn |
| 5 | United Therapeutics | 22.06 Bn | 19.40 Bn | 683.80 Mn | 372.70 Mn |
| 6 | Viatris | 18.84 Bn | 17.95 Bn | 1.46 Bn | -64.00 Mn |
| 7 | Neurocrine Biosciences | 15.55 Bn | 15.16 Bn | 935.80 Mn | 162.20 Mn |
| 8 | Vireo Growth | 11.86 Bn | 11.71 Bn | 59.30 Mn | -4.20 Mn |
| 9 | Elanco Animal Health | 11.77 Bn | 11.24 Bn | 798.00 Mn | 56.00 Mn |
| 10 | Amylyx Pharmaceuticals | 3.91 Bn | 3.91 Bn | - | -121.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -121.94 Mn |
| Mar 31, 2026 | -90.95 Mn |
| Dec 31, 2025 | -32.95 Mn |
| Sep 30, 2025 | -34.39 Mn |
| Jun 30, 2025 | -41.44 Mn |
| Mar 31, 2025 | -35.91 Mn |
| Dec 31, 2024 | -38.18 Mn |
| Sep 30, 2024 | -72.70 Mn |
| Jun 30, 2024 | -72.70 Mn |
| Mar 31, 2024 | -118.55 Mn |
| Dec 31, 2023 | 4.44 Mn |
| Sep 30, 2023 | 22.41 Mn |
| Jun 30, 2023 | 24.01 Mn |
| Mar 31, 2023 | 1.40 Mn |
| Dec 31, 2022 | -43.23 Mn |
| Sep 30, 2022 | -53.88 Mn |
| Jun 30, 2022 | -53.89 Mn |
| Mar 31, 2022 | -47.70 Mn |
| Dec 31, 2021 | -28.32 Mn |
| Sep 30, 2021 | -23.14 Mn |